Home
NewsNewsFertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
FertilAI announced on April 15, 2026, that it has received CE marking under the EU Medical Device Regulation (EU MDR) for its clinical decision-support tools. The clearance applies to StimAI and OvuPredict, which are integrated into the company’s Fertilane platform to assist physicians with clinical timing during active treatment cycles. This development introduces a regulated application of Predictive AI in Fertility specifically designed to predict mature oocyte yields and natural cycle ovulation. StimAI, an EU MDR Class IIa device, forecasts the number of mature oocytes retrieved across different trigger timings to support IVF outcomes and laboratory workload management. OvuPredict, classified as EU MDR Class I, predicts ovulation up to six days in advance to assist in timing intrauterine insemination (IUI) and frozen embryo transfers (FET).
The Fertilane system is a SaaS solution that integrates with existing electronic medical record (EMR) systems. Its algorithms were developed using data from more than 100,000 cycles to support individualized care and operational scheduling. By utilizing Predictive AI in Fertility, the platform aims to reduce patient monitoring requirements and balance daily clinic workloads without affecting clinical outcomes. The technology is intended to provide data-driven insights during active treatment cycles, allowing for more predictable daily scheduling in both medical and laboratory environments.
Fertilane delivers two fertility-tailored algorithms:
FertilAI CEO Rohi Hourvitz stated that the EU MDR validation confirms the technology’s role in streamlining clinic operations and increasing service access without raising overhead. The advancement of Predictive AI in Fertility is positioned to address physician shortages and rising infertility rates. Hourvitz commented, "Our goal is to accelerate and ease the patients' fertility treatment journey to parenthood, no matter the path taken". He added, "With the global rise in infertility and a worldwide shortage of physicians driving higher costs and longer wait times, expanding access to care is absolutely vital. Having a system that enables clinic scalability while actively improving clinical benefits and the patient experience is a pivotal step forward in addressing this growing challenge".
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
ARMS Embryo Watch offers time-lapse images of IVF embryos to patients by streaming each development stage and showing the output directly to the patient's device, enhancing transparency and emotional connection throughout the IVF journey.
